A detailed history of Thrivent Financial For Lutherans transactions in Abb Vie Inc. stock. As of the latest transaction made, Thrivent Financial For Lutherans holds 332,252 shares of ABBV stock, worth $59.8 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
332,252
Previous 268,778 23.62%
Holding current value
$59.8 Million
Previous $46.1 Million 42.32%
% of portfolio
0.12%
Previous 0.09%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$163.84 - $199.33 $10.4 Million - $12.7 Million
63,474 Added 23.62%
332,252 $65.6 Million
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $9.15 Million - $10.7 Million
-59,129 Reduced 18.03%
268,778 $46.1 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $12.1 Million - $13.8 Million
75,926 Added 30.13%
327,907 $59.7 Million
Q4 2023

Feb 14, 2024

SELL
$137.6 - $154.97 $2.61 Million - $2.94 Million
-18,999 Reduced 7.01%
251,981 $39 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $1.7 Million - $1.97 Million
12,747 Added 4.94%
270,980 $40.5 Million
Q2 2023

Aug 14, 2023

BUY
$132.51 - $164.9 $14.5 Million - $18.1 Million
109,722 Added 73.88%
258,233 $34.7 Million
Q1 2023

May 17, 2023

BUY
$144.61 - $166.54 $859,272 - $989,580
5,942 Added 4.17%
148,511 $23.6 Million
Q4 2022

Feb 08, 2023

BUY
$138.31 - $165.87 $52,972 - $63,528
383 Added 0.27%
142,569 $23.1 Million
Q3 2022

Nov 14, 2022

SELL
$134.21 - $153.93 $60.4 Million - $69.2 Million
-449,790 Reduced 75.98%
142,186 $19.4 Million
Q2 2022

Aug 16, 2022

SELL
$137.62 - $174.96 $20.1 Million - $25.6 Million
-146,079 Reduced 19.79%
591,976 $90.7 Million
Q1 2022

May 13, 2022

SELL
$131.98 - $163.75 $10.9 Million - $13.5 Million
-82,411 Reduced 10.04%
738,055 $119 Million
Q4 2021

Feb 16, 2022

BUY
$107.43 - $135.93 $9.25 Million - $11.7 Million
86,144 Added 11.73%
820,466 $109 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $23.3 Million - $26.4 Million
218,641 Added 42.4%
734,322 $79.3 Million
Q2 2021

Sep 24, 2021

BUY
$105.21 - $117.21 $5.41 Million - $6.03 Million
51,414 Added 11.07%
515,681 $58.1 Million
Q2 2021

Aug 19, 2021

SELL
$105.21 - $117.21 $1.22 Million - $1.35 Million
-11,555 Reduced 2.43%
464,267 $52.3 Million
Q1 2021

May 17, 2021

BUY
$102.3 - $112.62 $5.49 Million - $6.05 Million
53,710 Added 12.72%
475,822 $51.5 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $19.3 Million - $26 Million
239,319 Added 130.92%
422,112 $45.2 Million
Q3 2020

Nov 10, 2020

BUY
$85.91 - $100.83 $3.14 Million - $3.68 Million
36,502 Added 24.95%
182,793 $16 Million
Q2 2020

Aug 12, 2020

BUY
$73.37 - $98.18 $1.03 Million - $1.38 Million
14,062 Added 10.63%
146,291 $13.8 Million
Q1 2020

May 15, 2020

BUY
$64.5 - $97.79 $3.09 Million - $4.68 Million
47,907 Added 56.81%
132,229 $10.1 Million
Q4 2019

Feb 13, 2020

BUY
$72.13 - $90.25 $153,420 - $191,961
2,127 Added 2.59%
84,322 $7.47 Million
Q3 2019

Nov 14, 2019

BUY
$62.98 - $75.72 $31,049 - $37,329
493 Added 0.6%
82,195 $6.22 Million
Q2 2019

Aug 13, 2019

BUY
$65.7 - $83.98 $81,205 - $103,799
1,236 Added 1.54%
81,702 $5.94 Million
Q1 2019

May 14, 2019

SELL
$77.14 - $90.79 $154,665 - $182,033
-2,005 Reduced 2.43%
80,466 $6.49 Million
Q4 2018

Feb 15, 2019

BUY
$77.85 - $96.01 $90,928 - $112,139
1,168 Added 1.44%
82,471 $7.64 Million
Q3 2018

Nov 15, 2018

BUY
$88.91 - $98.84 $172,752 - $192,046
1,943 Added 2.45%
81,303 $7.69 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $161,155 - $190,682
1,795 Added 2.31%
79,360 $7.35 Million
Q1 2018

May 08, 2018

BUY
$92.01 - $123.21 $166,906 - $223,502
1,814 Added 2.39%
77,565 $7.34 Million
Q4 2017

Feb 14, 2018

BUY
$89.56 - $98.21 $814,100 - $892,728
9,090 Added 13.64%
75,751 $7.33 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $4.66 Million - $5.95 Million
66,661
66,661 $5.92 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Thrivent Financial For Lutherans Portfolio

Follow Thrivent Financial For Lutherans and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

News

Stay updated on Thrivent Financial For Lutherans with notifications on news.